Aardvark Therapeutics (AARD) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Aardvark Therapeutics (AARD) over the past year, gaining 23.2% versus a loss of 72.5%. Aardvark Therapeutics is the larger company by market cap ($103.1 million vs $102.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | KZIA |
|---|---|---|
| Share price | $4.71 | $8.95 |
| Market cap | $103.08M | $102.27M |
| 1-day change | 0.00% | +1.47% |
| YTD return | -64.11% | +28.01% |
| 1-year return | -72.50% | +23.18% |
| 5-year return | — | -98.32% |
| EPS (TTM) | $-3.21 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $17.40 |
| 52-week low | $3.35 | $4.86 |
| Distance from 52-week high | -72.38% | -48.56% |
| Analyst consensus | buy | none |
| Avg. price target upside | +135.88% | +215.75% |
| Average volume | 208.11K | 262.41K |
| Shares outstanding | 21.88M | 11.43M |
| Employees | 28 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed AARD by 95.7 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
AARD vs KZIA FAQ
Which is bigger, Aardvark Therapeutics or Kazia Therapeutics?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $103.08M compared with $102.27M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, AARD or KZIA?
KZIA returned +23.18% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.